Corxel's oral GLP-1 pill lands $377 million and a route to Nasdaq.

What Amanat and Corxel actually agreed to

Amanat Acquisition Corp (Nasdaq: AMAN), a blank check company, signed a definitive agreement on October 25 to merge with Corxel Pharmaceuticals, the obesity-focused arm of biopharma group Corxel. The deal is a SPAC business combination, not a conventional IPO: Corxel becomes a subsidiary of the combined company, which will trade under a new name and ticker once the deal closes.

The money comes from two places. Roughly $75 million is already sitting in Amanat's trust account, and an oversubscribed $300 million private placement is coming from investors including RTW Investments, New Enterprise Associates, SR One and RA Capital Management. Add it up and Corxel US expects about $377 million in gross proceeds, before costs and assuming shareholders don't cash out their shares ahead of the vote. Our coverage of Rightway's $155 million raise shows how much capital is still chasing the GLP-1 boom from every angle: insurers, pharmacy benefit managers and now drugmakers themselves.

That cash is meant to fund Corxel through 2029 and pay for a global Phase 3 program for its lead drug, CX11. The deal itself isn't expected to close until the first half of 2027, pending shareholder and Nasdaq approval.

The science behind CX11, Corxel's oral GLP-1 pill

CX11 is a once-daily oral small-molecule GLP-1 receptor agonist, the same drug class as Ozempic and Wegovy, just swallowed instead of injected. In a US Phase 2 obesity trial, patients lost up to 11.5% of their body weight after 36 weeks on the best-performing dose, against 3.1% on placebo. Doses ranged from 120mg (9.3% loss) up to 200mg (10.3% to 10.9% loss, depending on how quickly patients were titrated up).

Side effects were the usual GLP-1 complaints. Nausea hit 33% to 34% of patients, vomiting 12% to 16%, diarrhea and constipation up to 12% each. Corxel says none of it was severe, and 5% of patients quit the trial over GI issues, a rate roughly in line with injectable GLP-1s already on the market. After an end-of-Phase 2 meeting, the company says it has aligned with the FDA on the design of a pivotal Phase 3 trial. More than 1,500 people have now taken CX11 across its combined studies.

How CX11 stacks up against the pills already here

This is the part the deal's own press release skips over. CX11 isn't racing into an empty field. Novo Nordisk's oral Wegovy pill won FDA approval in December 2025, and patients who stayed on it for 64 weeks lost close to 17% of their body weight. Eli Lilly's orforglipron, still awaiting approval, posted 9.4% to 14.7% weight loss at 36 weeks in its own Phase 2 trial, with a decision possibly as early as 2026.

Set next to those numbers, CX11's 11.5% at 36 weeks is respectable but not best in class. It sits closer to the middle of the pack than ahead of it, and all three trials differ in dose, population and design, so none of this is a head-to-head comparison. What CX11 does have going for it is optionality: a second mechanism, the amylin agonist CX12, still in preclinical testing, and a Chinese Phase 3 trial run by licensing partner Vincentage that reported slightly stronger numbers, up to 12.4% weight loss over 52 weeks, with a new-drug application already filed in China.

Why a SPAC, and not an IPO

Corxel isn't filing for a traditional initial public offering. It's merging into an already-public shell company, a route that's typically faster and skips some of the scrutiny of a fresh S-1 filing, but carries its own risks. Amanat's existing shareholders can redeem their shares for cash before the vote, which could shrink the pot of money available. PIPE investors get a built-in mechanism to reduce their own commitment if that happens. None of this is unusual for a biotech SPAC, but it means the $377 million figure is a ceiling, not a guarantee, and our wider industry and business coverage has tracked several similar structures funding obesity-adjacent bets this year.

What this means for anyone watching the GLP-1 pill race

Nothing changes for patients today. Corxel's own investor materials target a Phase 3 start in 2027, an FDA filing by 2029, and a launch no earlier than 2030 or 2031, assuming everything goes to plan. That's years behind the oral Wegovy pill already on pharmacy shelves and Lilly's orforglipron, which could win approval well before Corxel even finishes its pivotal trial.

Our take

Corxel's $377 million is real money, and its Phase 2 data is real science, not vaporware. But the deal's framing of CX11 as a "differentiated, next-generation" pill oversells a drug that trails the two oral GLP-1s already ahead of it in development. The more interesting story here is what the deal says about the market: investors are still willing to fund a third or fourth mover in obesity drugs, years before it can reach a pharmacy shelf. For readers already on a GLP-1, this deal changes nothing about your options or your bill, at least not for several years.

Health Trend Wire holds no position in Corxel and was not paid for this article. This is general information, not medical or financial advice.